drugset

drugset / Trial / NCT01462643

Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test

NCT01462643 ↗

Phase 2 Completed 22 enrolled Almirall, S.A. proDERM GmbH · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of the exploratory study is to compare dose related effects of LAS41004 formulations in a non-occlusive PPT.

Timeline

Start: 2011-08
Primary completion: 2011-09
Completion: 2011-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LAS41004	Unknown	100 ug	Topical

Indications